All Posts

There’s good news on the treatment horizon for two typically slow-growing versions of lymphoma: follicular lymphoma and marginal zone lymphoma. Research presented by physicians from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, at the American Society of Hematology’s 2024 meeting in San Diego describes positive results for the antibody drug loncastuximab tesirine (Zynlonta) in patients with high-risk forms of these two blood cancers.

Advances in treatment including surgical innovations are helping women and their health care teams personalize care and improve quality of life.

Cancer is never part of the plan, nor is giving up the dream of having children. UF Health’s Oncofertility Program empowers patients with cancer to take control of their future by preserving their fertility.

By bringing together clinicians, patient advocates and researchers across disciplines, the UF Cardio-Oncology Symposium on April 3 provided an engaging forum to spark new research collaborations. The event showcased how innovations in precision medicine, early detection and multidisciplinary collaboration are directly enhancing patient care, ensuring the cancer patient of today does not become the cardiac patient of tomorrow.

New research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, scientists has found that targeting ZNF638, a “master regulator” protein that silences retroviruses, can induce an antiviral response in glioblastoma.

A UF researcher has launched a new clinical trial to test a novel UF-developed mRNA lipid nanoparticle (RNA-LP) that is designed to reprogram the immune system in two pediatric cancers.

When he retired to Sebring from Atlanta in 2014, Dennis Davis had a plan: fish and spend time with his wife, Deb. Despite ongoing treatment for prostate cancer and tongue cancer, the 75-year-old said he has been able to do that thanks to the ongoing care he’s received at Moffitt Cancer Center. It’s a two-plus hour drive to Tampa for his appointments, but he’s more than happy to make the trek, he said.

For cancers of organs like the liver, the long-term impact of our diet has been well studied — so much so that we have guidance about red meat, wine and other delicacies.

Immune checkpoint inhibitors have been a game-changer in oncology. Tumors often have proteins on them that tell your immune system not to attack. Checkpoint inhibitors — which work by blocking these proteins so your immune system continues to fight the tumor — have provided new options for many people with advanced or metastatic cancer who were left with limited options.

Adding one drug to a chemotherapy regimen for children with acute lymphoblastic leukemia decreased risk of relapse by about two-thirds, according to a study designed in part by John Kairalla, Ph.D., the senior statistician on the clinical trial and research associate professor and associate program director of the Children’s Oncology Group Statistics and Data Center in the College of Public Health and Health Professions’ Department of Biostatistics.